New technologies and computational methods are two main drivers of recent advancements in oncology. Next-generation sequencing (whole genome, exome, targeted sequencing) has become an indispensable tool in the study of cancer biology. As a result, molecular portraits associated with distinct clinical outcomes or predictive of response to targeted therapies have emerged in various solid tumors, paving the way for improved clinical management through the development of precision medicine [1–3].

...

The expectation that our increased understanding of cancer through genomics would lead to a proportional increase in the approval of novel targeted therapies and, ultimately, to improved patient outcomes has fallen short. Aside from a few successful examples (EGFR, HER2, BRAF, ALK, cKIT, etc.), the results of a genomic only approach in precision...

Article PDF first page preview

Article PDF first page preview
Article PDF first page preview
You do not currently have access to this article.